ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SIBN SI BONE Inc

15.58
0.00 (0.00%)
Pre Market
Last Updated: 09:09:37
Delayed by 15 minutes
Share Name Share Symbol Market Type
SI BONE Inc NASDAQ:SIBN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 15.58 10.19 24.77 0 09:09:37

SI-BONE to Present at the Canaccord Genuity Musculoskeletal Conference

28/02/2019 9:05pm

GlobeNewswire Inc.


SI BONE (NASDAQ:SIBN)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more SI BONE Charts.

­


SI-BONE, Inc., (Nasdaq: SIBN), a medical device company that is pioneering the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced the company will be participating in the upcoming Canaccord Genuity Musculoskeletal Conference in Las Vegas, Nevada.

SI-BONE’s management is scheduled to present on Tuesday, March 12, 2019 at 2:30 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.si-bone.com.

About SI-BONESI-BONE is a medical device company that pioneered the iFuse Implant System, a minimally invasive surgical system for fusion of the sacroiliac joint to treat sacroiliac joint dysfunction.  The SI joint is believed to be the last major joint with a clinically proven surgical treatment.  The iFuse Implant, commercially available since 2009, is believed to be the only SI joint fusion device supported by multiple prospective clinical studies showing improved pain, patient function and quality of life resulting from treatment.  There are over 60 peer-reviewed publications supporting the safety, effectiveness, and biomechanical and economic benefits unique to the iFuse Implant.  This body of evidence has enabled multiple government and private payers to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.  This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. There are potential risks associated with the iFuse Implant System.  It may not be appropriate for all patients and all patients may not benefit.

SOURCE SI-BONE, Inc.

Investor Contacts: Lynn Lewis or Carrie Mendivilinvestors@SI-BONE.com415-937-5405

1 Year SI BONE Chart

1 Year SI BONE Chart

1 Month SI BONE Chart

1 Month SI BONE Chart